Traders should anticipate a temporary drop in liquidity and potential volatility around the March 31 effective date due to the reverse split. Monitor whether the post-split share price sustains above $1 to assess Nasdaq compliance risk resolution.
Price Chart
Executive Summary
Akari Therapeutics is executing a 1-for-40 reverse split of its ADS ratio, reducing the number of ordinary shares per ADS from 2,000 to 80,000, effective March 31, 2026. The move is intended to help the company regain compliance with Nasdaq's minimum bid price listing requirement. No changes to the underlying ordinary shares or ticker symbol (AKTX) are made.
Key Facts
- Akari Therapeutics is changing its ADS ratio from 1 ADS = 2,000 ordinary shares to 1 ADS = 80,000 ordinary shares.
- This constitutes a 1-for-40 reverse split of ADSs, effective March 31, 2026.
- The purpose is to meet Nasdaq’s minimum bid price requirement for continued listing.
- ADS holders will exchange 40 old ADSs for 1 new ADS; fractional entitlements will be sold for cash.
- No changes to underlying ordinary shares or ticker symbol (AKTX) on Nasdaq.
- Deutsche Bank will manage the ADS exchange process.
Financial Impact
No direct financial impact — this is a structural change to maintain listing status. No new capital raised or dilution incurred.
Risk Factors
- Reverse split may signal financial distress and could negatively impact investor sentiment.
- No assurance that the bid price will remain above Nasdaq’s minimum after the ratio change.
- Potential for reduced retail investor interest post-split due to higher per-share price.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257683 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 25d ago | DEF 14A | $8.72 | awaiting T+60 | — | $8.48 (−2.75%) |
Oct 1, 2026 25d ago | 8-K | $8.72 | awaiting T+60 | — | $8.48 (−2.75%) |
Aug 13, 2026 10w ago | 8-K | $7.54 | awaiting T+60 | — | $8.48 (+12.47%) |
Jul 14, 2026 15w ago | EFFECT | $13.42 $8.63 | ▲ +35.73% | ▲ +39.11% | $8.48 (+36.81%) |
Jul 8, 2026 15w ago | EFFECT | $14.21 $8.84 | ▼ −37.79% | ▼ −40.28% | $8.48 (−40.32%) |
Jul 2, 2026 16w ago | S-3 | $10.41 $9.81 | ▲ +5.76% | ▲ +9.33% | $8.48 (+18.54%) |
Jun 29, 2026 17w ago | Press Release | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $8.48 (−12.49%) |
Jun 26, 2026 17w ago | 8-K | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $8.48 (−12.49%) |
May 28, 2026 21w ago | Press Release | $22.05 $7.85 | ▼ −64.40% | ▼ −66.13% | $8.48 (−61.54%) |
May 22, 2026 22w ago | 8-K | $17.81 $7.90 | ▲ +55.64% | ▲ +58.37% | $8.48 (+52.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers